At-home sampling to meet geographical challenges for serological assessment of SARS-CoV-2 exposure in a rural region of northern Sweden, March to May 2021: a retrospective cohort study.

Julia Wigren Byström, Linnea Vikström, Ebba Rosendal, Remigius Gröning, Yong-Dae Gwon, Emma Nilsson, Atin Sharma, Akbar Espaillat, Leo Hanke, Gerald McInerney, Andrea Puhar, Felipe Cava, Gunilla B Karlsson Hedestam, Therese Thunberg, Tor Monsen, Fredrik Elgh, Magnus Evander, Anders F Johansson, Anna K Överby, Clas Ahlm, Johan Normark, Mattias Ne Forsell
Author Information
  1. Julia Wigren Byström: Xerum AB, Umeå, Sweden.
  2. Linnea Vikström: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  3. Ebba Rosendal: Laboratory for Molecular Infection Medicine Sweden, Umeå University, Umeå, Sweden.
  4. Remigius Gröning: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  5. Yong-Dae Gwon: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  6. Emma Nilsson: Laboratory for Molecular Infection Medicine Sweden, Umeå University, Umeå, Sweden.
  7. Atin Sharma: Department of Molecular Biology, Umeå University, Umeå, Sweden.
  8. Akbar Espaillat: Department of Molecular Biology, Umeå University, Umeå, Sweden.
  9. Leo Hanke: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  10. Gerald McInerney: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  11. Andrea Puhar: Department of Molecular Biology, Umeå University, Umeå, Sweden.
  12. Felipe Cava: Department of Molecular Biology, Umeå University, Umeå, Sweden.
  13. Gunilla B Karlsson Hedestam: Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  14. Therese Thunberg: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  15. Tor Monsen: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  16. Fredrik Elgh: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  17. Magnus Evander: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  18. Anders F Johansson: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  19. Anna K Överby: Laboratory for Molecular Infection Medicine Sweden, Umeå University, Umeå, Sweden.
  20. Clas Ahlm: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  21. Johan Normark: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.
  22. Mattias Ne Forsell: Department of Clinical Microbiology, Umeå University, Umeå, Sweden.

Abstract

BackgroundThe current SARS-CoV-2 pandemic has highlighted a need for easy and safe blood sampling in combination with accurate serological methodology. Venipuncture for testing is usually performed by trained staff at healthcare centres. Long travel distances to healthcare centres in rural regions may introduce a bias of testing towards relatively large communities with closer access. Rural regions are therefore often not represented in population-based data.AimThe aim of this retrospective cohort study was to develop and implement a strategy for at-home testing in a rural region of Sweden during spring 2021, and to evaluate its role to provide equal health care for its inhabitants.MethodsWe developed a sensitive method to measure antibodies to the S-protein of SARS-CoV-2 and optimised this assay for clinical use together with a strategy of at-home capillary blood sampling.ResultsWe demonstrated that our ELISA gave comparable results after analysis of capillary blood or serum from SARS-CoV-2-experienced individuals. We demonstrated stability of the assay under conditions that reflected temperature and humidity during winter or summer. By assessment of capillary blood samples from 4,122 individuals, we could show both feasibility of the strategy and that implementation shifted the geographical spread of testing in favour of rural areas.ConclusionImplementation of at-home sampling enabled citizens living in remote rural areas access to centralised and sensitive laboratory antibody tests. The strategy for testing used here could therefore enable disease control authorities to get rapid access to information concerning immunity to infectious diseases, even across vast geographical distance.

Keywords

References

  1. Science. 2020 Mar 13;367(6483):1260-1263 [PMID: 32075877]
  2. J Med Virol. 2020 Jun;92(6):568-576 [PMID: 32134116]
  3. Int J Infect Dis. 2021 Oct;111:253-260 [PMID: 34419584]
  4. Nat Commun. 2021 Jun 17;12(1):3695 [PMID: 34140485]
  5. Nat Commun. 2021 Jan 4;12(1):113 [PMID: 33397956]
  6. Ann Epidemiol. 2021 Nov;63:75-78 [PMID: 34425208]
  7. Thorax. 2020 Aug;75(8):693-694 [PMID: 32461231]
  8. Sci Rep. 2022 Jun 25;12(1):10816 [PMID: 35752708]
  9. N Engl J Med. 2022 Jun 9;386(23):2201-2212 [PMID: 35613036]
  10. J Clin Virol. 2022 Oct;155:105270 [PMID: 36027822]
  11. Microbiol Spectr. 2022 Apr 27;10(2):e0155321 [PMID: 35319248]
  12. Microbiol Spectr. 2022 Jun 29;10(3):e0247121 [PMID: 35612315]
  13. Epidemiology. 2021 Jul 1;32(4):518-524 [PMID: 33935138]
  14. N Engl J Med. 2022 Mar 31;386(13):1288-1290 [PMID: 35139269]
  15. J Public Health (Oxf). 2022 Jun 27;44(2):e260-e263 [PMID: 33611565]
  16. Clin Transl Immunology. 2022 Mar 02;11(3):e1379 [PMID: 35284072]
  17. Nat Med. 2020 Jul;26(7):1033-1036 [PMID: 32398876]
  18. Cell. 2020 Jun 25;181(7):1489-1501.e15 [PMID: 32473127]
  19. EBioMedicine. 2021 Aug;70:103502 [PMID: 34333234]
  20. Sci Rep. 2021 Apr 7;11(1):7614 [PMID: 33828214]
  21. Clin Transl Immunology. 2021 Jul 19;10(7):e1312 [PMID: 34295471]
  22. Lancet Infect Dis. 2022 Dec;22(12):1649 [PMID: 36372089]
  23. Nat Med. 2020 Jun;26(6):845-848 [PMID: 32350462]
  24. Nat Commun. 2020 Jul 6;11(1):3436 [PMID: 32632160]
  25. Lancet Reg Health Eur. 2022 Sep;20:100452 [PMID: 35791335]
  26. Nat Rev Immunol. 2020 Oct;20(10):581-582 [PMID: 32839569]
  27. Trends Immunol. 2020 May;41(5):355-359 [PMID: 32249063]
  28. Viruses. 2022 Nov 15;14(11): [PMID: 36423134]
  29. Lancet Infect Dis. 2023 Feb;23(2):167-176 [PMID: 36270311]
  30. Lancet Infect Dis. 2020 May;20(5):565-574 [PMID: 32213337]
  31. Emerg Infect Dis. 2020 Jul;26(7):1478-1488 [PMID: 32267220]
  32. Cell. 2020 Apr 16;181(2):271-280.e8 [PMID: 32142651]
  33. Science. 2020 Jun 5;368(6495):1060-1061 [PMID: 32414781]
  34. Lancet Respir Med. 2021 Dec;9(12):1450-1466 [PMID: 34688434]
  35. Malar J. 2022 Jul 14;21(1):221 [PMID: 35836179]

MeSH Term

Humans
SARS-CoV-2
COVID-19
Retrospective Studies
Sweden
COVID-19 Testing
Antibodies, Viral

Chemicals

Antibodies, Viral

Word Cloud

Created with Highcharts 10.0.0testingruralbloodsamplingstrategySARS-CoV-2accessat-homeSwedencapillarygeographicalserologicalhealthcarecentresregionsthereforeretrospectivecohortstudyregionsensitiveassaydemonstratedindividualsassessmentareaslaboratorydiseaseBackgroundThecurrentpandemichighlightedneedeasysafecombinationaccuratemethodologyVenipunctureusuallyperformedtrainedstaffLongtraveldistancesmayintroducebiastowardsrelativelylargecommunitiescloserRuraloftenrepresentedpopulation-baseddataAimTheaimdevelopimplementspring2021evaluateroleprovideequalhealthcareinhabitantsMethodsWedevelopedmethodmeasureantibodiesS-proteinoptimisedclinicalusetogetherResultsWeELISAgavecomparableresultsanalysisserumSARS-CoV-2-experiencedstabilityconditionsreflectedtemperaturehumiditywintersummersamples4122showfeasibilityimplementationshiftedspreadfavourConclusionImplementationenabledcitizenslivingremotecentralisedantibodytestsusedenablecontrolauthoritiesgetrapidinformationconcerningimmunityinfectiousdiseasesevenacrossvastdistanceAt-homemeetchallengesexposurenorthernMarchMay2021:coronavirusCOVID-19surveillance

Similar Articles

Cited By (4)